Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin

Nathan L. Kleinman, Alesia Sadosky, Jaren Seid, Roy C. Martin, David M Labiner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Background/objective: Few studies have examined cost of illness of epileptic partial onset seizures (POS) from the employer perspective or compared users of gabapentin and pregabalin in treatment of POS. This study compares pharmacotherapy, direct/indirect costs, and work absences of patients with POS newly started on gabapentin or pregabalin. Methods: Data from employees and dependent spouses with POS starting treatment (index date) with either gabapentin or pregabalin were analyzed. Patients were required to have at least 6 months of health plan enrollment pre- and post-index. Regression modeling compared medical and prescription costs, sick leave (SL), short-term disability (STD), workers' compensation (WC) costs and absence days during the 6-month post-index period. Persistence, adherence (proportion of days covered), impact on adherence of copay, and copay as a percent of salary were modeled. Results: Semiannual medical, drug, SL, STD, and WC costs for gabapentin vs. pregabalin cohorts were $10,306 vs. $9186, $2353 vs. $3387 (P= 0.01), $552 vs. $342, $1280 vs. $580, and $170 vs. $30, respectively. SL days (10.8 vs. 1.5, P= 0.04) and STD days (9.8 vs. 6.2) were lower in the pregabalin cohort. Persistence (median 94 vs. 70 days) and proportion with ≥80% adherence (30% vs. 15%, P= 0.049) were greater in the pregabalin cohort. Adherence decreased as copay or copay as a percent of salary increased beyond specific levels in both cohorts. Conclusion: Despite higher acquisition costs for branded pregabalin over generic gabapentin, overall direct and indirect costs trended lower for pregabalin users. Additionally, pregabalin users had significantly fewer sick leave days and significantly higher adherence rates than gabapentin users.

Original languageEnglish (US)
Pages (from-to)13-22
Number of pages10
JournalEpilepsy Research
Volume102
Issue number1-2
DOIs
StatePublished - Nov 2012

Fingerprint

Patient Compliance
Sick Leave
Seizures
Costs and Cost Analysis
Workers' Compensation
Salaries and Fringe Benefits
gabapentin
Pregabalin
Cost of Illness
Spouses
Prescriptions
Drug Therapy
Health
Therapeutics
Pharmaceutical Preparations

Keywords

  • Adherence
  • Costs
  • Gabapentin
  • Partial onset seizures
  • Pregabalin
  • Work absence

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. / Kleinman, Nathan L.; Sadosky, Alesia; Seid, Jaren; Martin, Roy C.; Labiner, David M.

In: Epilepsy Research, Vol. 102, No. 1-2, 11.2012, p. 13-22.

Research output: Contribution to journalArticle

Kleinman, Nathan L. ; Sadosky, Alesia ; Seid, Jaren ; Martin, Roy C. ; Labiner, David M. / Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin. In: Epilepsy Research. 2012 ; Vol. 102, No. 1-2. pp. 13-22.
@article{21912829746a4c81ae5856a3a18a9a0d,
title = "Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin",
abstract = "Background/objective: Few studies have examined cost of illness of epileptic partial onset seizures (POS) from the employer perspective or compared users of gabapentin and pregabalin in treatment of POS. This study compares pharmacotherapy, direct/indirect costs, and work absences of patients with POS newly started on gabapentin or pregabalin. Methods: Data from employees and dependent spouses with POS starting treatment (index date) with either gabapentin or pregabalin were analyzed. Patients were required to have at least 6 months of health plan enrollment pre- and post-index. Regression modeling compared medical and prescription costs, sick leave (SL), short-term disability (STD), workers' compensation (WC) costs and absence days during the 6-month post-index period. Persistence, adherence (proportion of days covered), impact on adherence of copay, and copay as a percent of salary were modeled. Results: Semiannual medical, drug, SL, STD, and WC costs for gabapentin vs. pregabalin cohorts were $10,306 vs. $9186, $2353 vs. $3387 (P= 0.01), $552 vs. $342, $1280 vs. $580, and $170 vs. $30, respectively. SL days (10.8 vs. 1.5, P= 0.04) and STD days (9.8 vs. 6.2) were lower in the pregabalin cohort. Persistence (median 94 vs. 70 days) and proportion with ≥80{\%} adherence (30{\%} vs. 15{\%}, P= 0.049) were greater in the pregabalin cohort. Adherence decreased as copay or copay as a percent of salary increased beyond specific levels in both cohorts. Conclusion: Despite higher acquisition costs for branded pregabalin over generic gabapentin, overall direct and indirect costs trended lower for pregabalin users. Additionally, pregabalin users had significantly fewer sick leave days and significantly higher adherence rates than gabapentin users.",
keywords = "Adherence, Costs, Gabapentin, Partial onset seizures, Pregabalin, Work absence",
author = "Kleinman, {Nathan L.} and Alesia Sadosky and Jaren Seid and Martin, {Roy C.} and Labiner, {David M}",
year = "2012",
month = "11",
doi = "10.1016/j.eplepsyres.2012.04.019",
language = "English (US)",
volume = "102",
pages = "13--22",
journal = "Epilepsy Research",
issn = "0920-1211",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - Costs, work absence, and adherence in patients with partial onset seizures prescribed gabapentin or pregabalin

AU - Kleinman, Nathan L.

AU - Sadosky, Alesia

AU - Seid, Jaren

AU - Martin, Roy C.

AU - Labiner, David M

PY - 2012/11

Y1 - 2012/11

N2 - Background/objective: Few studies have examined cost of illness of epileptic partial onset seizures (POS) from the employer perspective or compared users of gabapentin and pregabalin in treatment of POS. This study compares pharmacotherapy, direct/indirect costs, and work absences of patients with POS newly started on gabapentin or pregabalin. Methods: Data from employees and dependent spouses with POS starting treatment (index date) with either gabapentin or pregabalin were analyzed. Patients were required to have at least 6 months of health plan enrollment pre- and post-index. Regression modeling compared medical and prescription costs, sick leave (SL), short-term disability (STD), workers' compensation (WC) costs and absence days during the 6-month post-index period. Persistence, adherence (proportion of days covered), impact on adherence of copay, and copay as a percent of salary were modeled. Results: Semiannual medical, drug, SL, STD, and WC costs for gabapentin vs. pregabalin cohorts were $10,306 vs. $9186, $2353 vs. $3387 (P= 0.01), $552 vs. $342, $1280 vs. $580, and $170 vs. $30, respectively. SL days (10.8 vs. 1.5, P= 0.04) and STD days (9.8 vs. 6.2) were lower in the pregabalin cohort. Persistence (median 94 vs. 70 days) and proportion with ≥80% adherence (30% vs. 15%, P= 0.049) were greater in the pregabalin cohort. Adherence decreased as copay or copay as a percent of salary increased beyond specific levels in both cohorts. Conclusion: Despite higher acquisition costs for branded pregabalin over generic gabapentin, overall direct and indirect costs trended lower for pregabalin users. Additionally, pregabalin users had significantly fewer sick leave days and significantly higher adherence rates than gabapentin users.

AB - Background/objective: Few studies have examined cost of illness of epileptic partial onset seizures (POS) from the employer perspective or compared users of gabapentin and pregabalin in treatment of POS. This study compares pharmacotherapy, direct/indirect costs, and work absences of patients with POS newly started on gabapentin or pregabalin. Methods: Data from employees and dependent spouses with POS starting treatment (index date) with either gabapentin or pregabalin were analyzed. Patients were required to have at least 6 months of health plan enrollment pre- and post-index. Regression modeling compared medical and prescription costs, sick leave (SL), short-term disability (STD), workers' compensation (WC) costs and absence days during the 6-month post-index period. Persistence, adherence (proportion of days covered), impact on adherence of copay, and copay as a percent of salary were modeled. Results: Semiannual medical, drug, SL, STD, and WC costs for gabapentin vs. pregabalin cohorts were $10,306 vs. $9186, $2353 vs. $3387 (P= 0.01), $552 vs. $342, $1280 vs. $580, and $170 vs. $30, respectively. SL days (10.8 vs. 1.5, P= 0.04) and STD days (9.8 vs. 6.2) were lower in the pregabalin cohort. Persistence (median 94 vs. 70 days) and proportion with ≥80% adherence (30% vs. 15%, P= 0.049) were greater in the pregabalin cohort. Adherence decreased as copay or copay as a percent of salary increased beyond specific levels in both cohorts. Conclusion: Despite higher acquisition costs for branded pregabalin over generic gabapentin, overall direct and indirect costs trended lower for pregabalin users. Additionally, pregabalin users had significantly fewer sick leave days and significantly higher adherence rates than gabapentin users.

KW - Adherence

KW - Costs

KW - Gabapentin

KW - Partial onset seizures

KW - Pregabalin

KW - Work absence

UR - http://www.scopus.com/inward/record.url?scp=84868301197&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868301197&partnerID=8YFLogxK

U2 - 10.1016/j.eplepsyres.2012.04.019

DO - 10.1016/j.eplepsyres.2012.04.019

M3 - Article

C2 - 22591752

AN - SCOPUS:84868301197

VL - 102

SP - 13

EP - 22

JO - Epilepsy Research

JF - Epilepsy Research

SN - 0920-1211

IS - 1-2

ER -